Summary

U.S. Antibiotics Market Summary

The U.S. antibiotics market size was estimated at USD 13.77 billion in 2024 and is projected to reach USD 16.46 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing prevalence of infectious diseases is a major factor contributing to market growth.

The increasing prevalence of infections in the elderly and chronically ill significantly drives the U.S. antibiotics market. In 2024, over 60 million Americans were aged 65 or older, a demographic highly susceptible to infections like pneumonia, UTIs, and sepsis. In addition to that, the rising incidence of chronic conditions such as diabetes, cancer, and COPD compromises immune systems, leading to a greater need for antibiotics. According to CDC, nearly 60% of U.S. adults have at least one chronic disease, further expanding the patient base requiring antibiotic treatment.

The increasing number of surgical procedures and advanced medical interventions significantly contribute to the demand for antibiotics in the U.S. market. Procedures such as organ transplants, cancer treatments, and orthopedic surgeries often carry a high risk of post-operative infections, making preventive and therapeutic antibiotics essential. Hospitals and outpatient facilities depend on effective antibiotic regimens to reduce complications and improve patient recovery. As access to these procedures expands, antibiotics play an even more critical role in ensuring positive patient outcomes, solidifying their position as a vital part of modern medical care.

The U.S. antibiotics market is growing due to cutting-edge R&D, substantial healthcare spending, and a strong emphasis on innovation. The country leads globally in developing next-generation antibiotics to counter AMR, supported by policies such as the Generating Antibiotic Incentives Now (GAIN) Act of 2012, which provides incentives such as extended exclusivity periods. A notable instance is the collaboration between Merck and the National Institute of Allergy and Infectious Diseases (NIAID) in 2023 to develop novel antibiotics targeting multidrug-resistant bacteria.
U.S. Antibiotics Market Report Segmentation

This report forecasts revenue growth at country level as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibiotics market report on the basis of action mechanism, type, and drug class:

• Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Branded Antibiotics
• Generic Anitbiotics
• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• 7-ACA
• Other

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.4. Information Procurement
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Antibiotics Market Variables, Trends & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. U.S. Antibiotics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Political landscape
3.4.1.2. Economic and Social landscape
3.4.1.3. Technological landscape
3.4.1.4. Environmental landscape
3.4.1.5. Legal landscape
3.4.2. PESTEL Analysis
3.4.2.1. Bargaining power of the suppliers
3.4.2.2. Bargaining power of the buyers
3.4.2.3. Threats of substitution
3.4.2.4. Threats from new entrants
3.4.2.5. Competitive rivalry
Chapter 4. U.S. Antibiotics Market: Action Mechanism Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Antibiotics Market: Action Mechanism Analysis, 2023 & 2030 (USD Million)
4.3. Cell Wall Synthesis Inhibitors
4.3.1. Cell Wall Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Protein Synthesis Inhibitors
4.4.1. Protein Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. DNA Synthesis Inhibitors
4.5.1. DNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. RNA Synthesis Inhibitors
4.6.1. RNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Mycolic Acid Inhibitors
4.7.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Antibiotics Market: Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Antibiotics Market: Type Analysis, 2023 & 2030 (USD Million)
5.3. Branded Antibiotics
5.3.1. Branded Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Generic Antibiotics
5.4.1. Generic Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Antibiotics Market: Drug Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Antibiotics Market: Drug Analysis, 2023 & 2030 (USD Million)
6.3. Cephalosporins
6.3.1. Cephalosporins Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Penicillin
6.4.1. Penicillin Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Fluoroquinolones
6.5.1. Fluoroquinolones Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Macrolides
6.6.1. Macrolides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Carbapenems
6.7.1. Carbapenems Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Aminoglycosides
6.8.1. Aminoglycosides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Sulfonamides
6.9.1. Sulfonamides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. 7-ACA
6.10.1. 7-ACA Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.11. Others
6.11.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. AbbeVie, Inc.
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Pfizer Inc.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Novartis AG
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Merck & Co., Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Teva Pharmaceutical Industries Ltd.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives